AccurEdit Therapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech pioneering in vivo CRISPR gene editing therapies with a lead program for ATTR and an integrated platform.
Genetic DiseasesCardiovascular
Technology Platform
An integrated end-to-end in vivo gene editing platform encompassing proprietary RNA synthesis, patented base editors/Cas enzymes for editing, and targeted delivery technologies, including LNP and next-generation polymers.
Opportunities
Potential to deliver a best-in-class, single-dose curative therapy for ATTR, validating its platform for expansion into other liver and non-liver targeted genetic diseases.
Risk Factors
Clinical and regulatory risks inherent to a first-in-class in vivo gene editing therapy, long-term safety uncertainties, and intense competition from well-funded global biotechs in the ATTR space.
Competitive Landscape
Competes with global leaders like Intellia Therapeutics and Verve Therapeutics in in vivo gene editing for ATTR/cardiovascular disease; differentiates through its integrated platform, rapid clinical execution in China, and early FDA RMAT designation.